DIY HRT carries real risks including blood clots, liver problems, and brain tumours with certain medications, but for many trans people it is the only option available. Supervised care with proper dosing and hormone monitoring is always safer. When supervised care is inaccessible, harm reduction strategies meaningfully reduce risk.
Why these medications require a prescription in the first place
These are prescription-only medicines for a reason. The dose has to be right. The drug has to be right. The hormone levels have to be monitored and adjusted over time. That is not bureaucratic gatekeeping; it is basic clinical sense. Get the dose wrong and you are either getting no benefit or exposing yourself to avoidable harm. Get the drug wrong and you may be taking something with a risk profile that doesn't fit your circumstances. This is why medically governed care matters, and why I say that clearly even when I know exactly why people end up going without it.
What worries me, and what I want to address honestly, is not that trans people are making foolish decisions. They are not. They are making the best decisions they can in a system that has repeatedly failed them. Service closures, years-long waiting lists, pharmacy refusals, and the political erosion of access have pushed people toward DIY not because it is ideal but because the alternative, waiting through an unwanted puberty or years of untreated dysphoria, causes its own serious harm. Delay is not neutral. Withholding care is not safety.
The specific risks of unsupervised hormone therapy
I want to name the risks specifically, because vague warnings do not help anyone make an informed decision.
Thrombosis
Oestrogen raises the risk of blood clots, and that risk is dose-dependent. With monitoring, a clinician can check that oestrogen levels stay within a range where the risk is manageable. Without monitoring, there is no way to know. The route of administration matters too: transdermal oestrogen (patches, gels) carries a lower clot risk than oral oestrogen because it bypasses first-pass liver metabolism. If you are sourcing your own oestrogen, transdermal is meaningfully safer.
Meningioma with cyproterone acetate
Cyproterone acetate (CPA), an anti-androgen used widely in trans feminine care in Europe, is associated with an increased risk of meningioma (a type of brain tumour, usually benign but capable of causing serious neurological harm) when used at high doses over long periods. The risk rises with cumulative dose: 25 mg daily over several years carries a different risk profile from 50 mg or 100 mg. French regulatory data flagged this clearly enough that CPA is now prescribed at much lower doses in supervised settings. Someone self-medicating with CPA without that context may be using doses and durations that significantly increase their risk. If CPA is part of your DIY regimen, lower doses and a clear intention to switch to a different anti-androgen when possible are the harm-reduction steps that matter most.
Liver stress
Certain anti-androgens, including high-dose synthetic progestogens, can affect liver function. This is rarely catastrophic in otherwise healthy people, but it is detectable with a simple blood test and invisible without one. Over time, undetected liver stress can compound into something more serious.
Dosing in the dark
Perhaps the most underrated risk of DIY is simply not knowing where your hormone levels actually sit. Hormones behave differently in different bodies. Someone taking the same patch dose as a friend may be running twice the oestrogen level, or half. Without blood tests, there is no feedback loop. You cannot know whether you are in the therapeutic range, whether your testosterone is being adequately suppressed, or whether you are overshooting in ways that raise your risk.
What supervised care actually provides
Good supervised care, following the WPATH Standards of Care 8 or the Endocrine Society guidelines, gives you a starting dose matched to your body, regular blood tests to check hormone levels and organ function, and a clinical relationship where the dose can be adjusted as your body responds. It also gives you access to the full range of formulations, so if one route or drug is not working well for you, there are alternatives.
That is the shape of good care. It is not an interrogation of your identity, not a series of psychological assessments before you are permitted to begin, and not a process designed to test whether you are trans enough. It is monitoring. It is dose adjustment. It is safety.
The tragedy is that this basic, sensible care is simply not available to most trans people on a public pathway. In the UK, NHS waiting lists run into years. Several private services have closed, including OpenGate and OGL, which has left people who were mid-treatment scrambling. The political climate has narrowed what is available further still.
The new pressures making DIY more common, not less
There are now additional structural barriers layering on top of the ones that were already there. Estradiol patches, one of the safest and most widely used forms of oestrogen, have faced supply shortages in several countries. When the pharmacies that stock them are already sparse, a shortage can mean going without, or turning to less well-monitored alternatives.
Some people are also encountering pharmacies that refuse to dispense hormones on religious or conscientious grounds. This is happening more visibly in certain parts of the United States following shifts in political and regulatory climate, but it is not confined there. Being turned away at a pharmacy when you have a valid prescription is not a minor inconvenience; it is a structural barrier to care that pushes people toward sourcing medication themselves.
I want to name something else that has been happening, because it needs naming. When HRT products become scarce, trans women are sometimes publicly blamed, as though their prescriptions are taking medication away from menopausal or perimenopausal women. This framing is wrong and it is harmful. Trans women are not responsible for pharmaceutical supply chain problems. Pitting two groups of women against each other over access to the same medications serves no one, and it is not a neutral observation; it is a hostile one, and it needs to be called what it is.
Harm reduction when supervised care is out of reach
If you are in a position where DIY is your only realistic option right now, these are the things that make the most meaningful difference to your safety.
Use transdermal oestrogen where you possibly can. Patches or gels are safer than oral tablets for most people, primarily because the clot risk is substantially lower. They are also more consistent in terms of blood levels.
Get blood tests done. Many private laboratories offer testing without a doctor's referral, and there are home finger-prick test kits available in several countries. Knowing your oestradiol level and your testosterone level tells you whether your regimen is doing what it should. Aim to test at least every few months when you are starting out, and every six months once things are stable.
If you are using cyproterone acetate, keep the dose as low as possible. The harm-reduction evidence points clearly toward lower cumulative doses reducing meningioma risk. Moving to a different anti-androgen, such as bicalutamide or a GnRH analogue if you can access one, removes the meningioma risk entirely.
Do not use injectable oestrogen without understanding the dosing very carefully. Injections produce large peaks and troughs in hormone levels that are difficult to manage without monitoring, and dosing errors carry a higher immediate risk than patches or gels.
Try to maintain a relationship with a clinician, even a cautious or imperfect one, for the monitoring piece. A doctor who will not prescribe but will order blood tests is still providing something valuable. A doctor who will look at your results and tell you whether something looks concerning is worth keeping in your corner even if they cannot prescribe what you need.
If there is a supervised pathway you can access, even a private one, it is worth prioritising. GenderGP at gendergp.com[1] provides affirming, supervised care using current international standards, and it exists precisely for situations where public services cannot reach people.
What I want people to hear
The people doing DIY HRT are not reckless. They are resourceful, often isolated, and trying to survive a system that was not built for them and has been actively dismantled in some places. My job is not to lecture them about the risks in a way that makes them feel worse about a decision they had no real alternative to. My job is to make sure they have the information they need to be as safe as possible while they navigate their way toward something better.
The risks are real and they are specific. Thrombosis, meningioma, liver stress, dosing in the dark: these are the things that can go wrong, and they are not inevitable. With the right harm-reduction steps, regular monitoring, and the least risky medications and routes, many people manage DIY without serious adverse effects. That is the honest picture.
But supervised care, real supervised care with blood tests and clinical support and dose adjustment, is always the goal. Not because trans people need to be monitored as a condition of their identity, but because everyone on hormone therapy benefits from knowing their levels are right. That is as true for a menopausal woman on HRT as it is for a trans woman on exactly the same medication.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a gender specialist, medical educator, and advocate, and the founder of GenderGP. She writes about gender diversity, trans healthcare, and the lives around them.
Comments